Association Between CYP2C19 Polymorphisms and Esophageal Squamous Cell Carcinoma Risk in Asian Populations: A Systematic Review and Meta-analysis

Xuehan Gao
Peking Union Medical College Hospital
https://orcid.org/0000-0003-4841-570X

Guige Wang
Peking Union Medical College Hospital

Lei Liu
Peking Union Medical College Hospital

Jiaqi Zhang
Peking Union Medical College Hospital

Ke Zhao
Peking Union Medical College Hospital

Yanqing Wang
Peking Union Medical College Hospital

Shanqing Li (✉ lsq2131@163.com )
https://orcid.org/0000-0001-5345-2340

Primary research

Keywords: CYP2C19, Esophageal squamous cell carcinoma, Polymorphism, Meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-33546/v1

License: ☺️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: This meta-analysis was performed to evaluate the association between CYP2C19 gene polymorphisms and ESCC risk in Asian populations.

Methods: A literature search was performed in main medical publication databases for the association between CYP2C19 gene polymorphisms and ESCC risk, up to May 2020. A random/fixed-effects model was used to calculate the pooled odds ratios (OR) and 95% confidence intervals (CI) to evaluate the associations, considering multiple genetic models. And people were classified into three groups according to metabolizer phenotypes: (i) extensive metabolizers (EMs: *1/*1, *1/*2, *1/*3); (ii) intermediate metabolizers (IMs: *1/*2, *1/*3) and (iii) poor metabolizers (PMs: *2/*2, *2/*3, *3/*3).

Results: Eight studies with 1955 cases and 2754 controls were ultimately included that showed that individuals carrying the “A” allele of CYP2C19*2 G681A and AA genotype of CYP2C19*3 G636A were significantly associated with an increased ESCC risk (CYP2C19*2 A vs. G: OR = 1.823, 95% CI = 1.616-2.056; CYP2C19*3 AA vs. AG + GG: OR = 2.992, 95% CI = 1.122-7.981). In the analysis of metabolizer phenotypes, PMs and IMs groups were associated with ESCC risk compared to EMs (IMs vs. EMs: OR = 1.673, 95% CI = 1.281-2.186; PMs vs. EMs: OR = 2.605, 95% CI = 1.945-3.489). And PMs showed a stronger correlation (PMs vs. IMs + EMs: OR = 2.220, 95% CI = 1.705-2.891).

Conclusions: Our meta-analysis revealed that “A” allele (AA+AG) of CYP2C19*2 and AA genotype of CYP2C19*3 polymorphism are significantly associated with ESCC risk. In metabolizer phenotypes, PMs and IMs are associated with an increased risk of ESCC in Asian populations.

Background

Esophageal carcinoma (EC) is one of the most aggressive cancers, with high mortality and low 5 years survival rate ranging from 4–40% [1]. According to GLOBOCAN 2018, EC is the ninth most common cancer and sixth leading cause of cancer death worldwide, with about 572,034 new cases and 508,584 deaths each year [2]. There are clear geographic variations of EC in both incidence and histological types. Esophageal adenocarcinoma (EADC) and esophageal squamous cell cancer (ESCC) are the two main histological types. EADC is more prevalent in western developed countries; ESCC is more common in Eastern Asia, Central Asia and Southern Africa which called “the esophageal cancer belt”, where nearly 90% of EC are ESCC [1, 3]. As early symptoms of ESCC may be subtle and nonspecific, most ESCC
patients had been the advanced stage at diagnosis, lead to a poor prognosis. It’s worth confirming pathogenesis and risk factors for ESCC.

Several exposures were related to the process of ESCC, including tobacco smoking, hot food and beverages, lack of vegetables and fruits, and HPV infection [4]. However, more evidences indicated that genetic predisposition, especially single-nucleotide polymorphisms, plays an important role in the development and progression of ESCC [5]. As a member of cytochrome P450 (CYP) superfamily, CYP2C19, also known as S-mephenytoin hydroxylase, is an important phase I metabolic enzyme. Cytochrome P450 2C19 (CYP2C19) is located on chromosome 10q24 and consists of 490 amine acids [6, 7]. There are at least 14 mutants and 18 alleles in CYP2C19 gene. CYP2C19*2 and CYP2C19*3 are the two commonest mutations, causing 99% people in Eastern countries to have poor metabolism [8, 9]. The mechanism of CYP2C19*2 mutation is a 681 substitution of guanine to adenine (G > A) in the exon 5, which lead to a 40 base pair fragment containing a Smal restriction endonuclease site to be lost in the initial segment of exon 5 during transcription, causing an inactive enzyme. The CYP2C19*3 polymorphism is a 636 substitution of guanine to adenine (G > A) in the exon 4, causing the codon of tryptophan changing to a stop codon, which lead to a premature termination of protein synthesis and a lack of connective zone of the substrate and the hemochrome [10]. According to metabolic capacity, CYP2C19 can be divided into three phenotypes: extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabolizers (PMs). Individuals with homozygous are EMs (*1/*1), which have efficient enzyme to metabolize CYP2C19 substrates [11, 12]. Individuals with heterozygous are IMs (*1/*2, *1/*3), which have intermediate enzyme to metabolize CYP2C19 substrates. Individuals with mutant CYP2C19 alleles are PMs (*2/*2, *3/*3 or *2/*3), which have a reduced capacity to metabolize CYP2C19 substrates [13]. The study intended to investigate the association of gene polymorphisms and metabolizer phenotypes of CYP2C19 with ESCC risk in Asian populations.

Materials And Methods

Literature search and selection criteria

We conducted a systematic literature search in PubMed, Web of Science, EMBASE, and China National Knowledge Internet (CNKI) databases. The search covered all publications before May, 2020. The used search terms included: “esophageal cancer” or “esophageal squamous cell carcinoma” or “ESCC” or “esophageal carcinoma” and “polymorphisms” or “SNP” or “variation” or “genetic” and “CYP2C19” or “Cytochrome P450 2C19” or “CYP 2C19” or “Cytochrome P2C19” or “rs4244285” or “rs4986893”. References from retrieved articles were searched manually for additional studies [14].

Inclusion and exclusion criteria

The inclusion criteria had to meet the following conditions: (1) case–control or retrospective cohort studies that evaluated the association between CYP2C19 polymorphisms and ESCC risk, (2) patients with pathologically or histologically confirmed diagnosis of ESCC, (3) independent genotype information of
CYP2C19*1, CYP2C19*2 and CYP2C19*3 polymorphisms, and (4) sufficient data that could evaluate odds ratio (OR) with 95% confidence interval [15].

In addition, the following exclusion criteria were used: (1) lack of sufficient data to extract the necessary information; (2) EADC studies or samples mixed with EADC, making it impossible to extract sufficient information, (3) Studies about other CYP2C19 genotypes (ie, CYP2C19*17), and (4) reviews, meta-analyses, case reports, in vitro cell line studies, and animal experiment studies. For each study, general characteristics including authors, year of publication, ethnicity, sample size, genotype, and allele frequencies were collected (Fig. 1).

Statistical analysis

In this study, a detailed meta-analysis was performed to reveal the association between CYP2C19*1 (G/G), CYP2C19*2 (G681A), CYP2C19*3 (G636A) polymorphisms and ESCC risk. Subgroup and metabolizer phenotypes analyses were performed on the original date to explore the potential heterogeneity among studies. Associations of CYP2C19*2 and *3 gene polymorphisms with ESCC risk were estimated by five contrasts: dominant genetic model, recessive genetic model, allele genetic mode, homozygote genetic model and heterozygote genetic model.

A formal Q statistical test, as well as $I^2$, was used to judge the heterogeneity among studies. A $P < 0.10$ or $I^2 > 50\%$ was considered to be a fixed-effect model; otherwise, a random-effect model was conducted [16]. Depending on the heterogeneity results, the pooled ORs with 95%CIs were calculated in a fixed-effect or random-effect model to evaluate the association of CYP2C19 polymorphisms with ESCC risk. A $P < 0.05$ was considered statistically significant. Sensitivity analysis was conducted to validate the stability of results by sequential omission of each study. Publication bias was evaluated by both Egger's regression test and Begg's adjusted rank correlation test of funnel plot. All tests in this meta-analysis were performed using STATA version 11.0 software (STATA Corporation, College Station, TX, USA).

Results

A total of 320 studies were identified from the database search. After carefully screening of titles or abstracts, 277 studies were excluded. Then, 31 studies were excluded based on the exclusion criteria. Finally, 8 studies were involved in this meta-analysis (Fig. 1). Among the 8 studies, data were available from 6 studies on the CYP2C19*2 genotype (970 cases and 1415 controls) and 6 studies on the CYP2C19*3 genotype (757 cases and 1164 controls). The information and characteristics of the included 8 studies were listed in Tables 1.

The quality of the included studies was evaluated using the Newcastle–Ottawa Scale (NOS). It is designed to assess studies in three components: the selection of the study groups (0–4 points), the comparability of the groups (0–2 points) and the determination of either the exposure or the outcome of
interest (0–3 points) [17]. A perfect NOS score is 9. In this meta-analysis, two studies scored 9 [18, 19]; four studies scored 8 [20–23]; two studies scored 7 [24, 25].

CYP2C19*2 (G681A) polymorphism and ESCC risk

A meta-analysis of CYP2C19*2 polymorphism and ESCC risk was conducted in all genetic models, which enrolled six studies and 2385 individuals. The detailed results were shown in Table 2. The pooled meta-analysis showed that compared to controls, an increased ESCC risk was observed in all genetic models: dominant model, AA + AG vs. GG (OR = 2.406, 95% CI = 2.013–2.876) (Fig. 2); recessive model, AA vs. AG + GG (OR = 1.934, 95% CI = 1.533–2.439); allele model, A vs. G (OR = 1.823, 95% CI = 1.616–2.056); homozygous model, AA vs. GG (OR = 4.467, 95% CI = 3.320–6.011); and heterozygous model, GA vs. GG (OR = 1.309, 95% CI = 1.073–1.596). According to the heterogeneity study, three genetic models (allele model: I² = 0.0%, P = 0.694; recessive model: I² = 23.2%, P = 0.260; dominant model: I² = 30.3%, P = 0.208) used the fixed-effect model and two genetic models (heterozygous model: I² = 92.2%, P = 0.000; homozygous model: I² = 97.2%, P = 0.000) used random-effect model.

CYP2C19*3 (G636A) polymorphism and ESCC risk

Six studies including 757 cases and 1164 controls described the association between the CYP2C19*3 polymorphism and ESCC risk. The pooled meta-analysis showed that there was a significant association between AA genotype of CYP2C19*3 polymorphism and ESCC risk under recessive model (AA vs. AG + GG: OR = 2.992, 95% CI = 1.122–7.981) (Fig. 3) and homozygote model (AA vs. GG: OR = 2.889, 95% CI = 1.073–7.776); but not in dominant, heterozygote and allele models (Table 2). For the zero events of CYP2C19*3 AA genotype in 2 studies included, only 4 studies including 545 cases and 694 controls were calculated in the recessive and homozygote models finally [26]. Heterogeneity assessment showed significant inter-study variation existed in three genetic models (dominant model: I² = 69.3%, P = 0.006; heterozygote model: I² = 85.1%, P = 0.000; allele model: I² = 70.7%, P = 0.004) and a random-effect model was used; no variation in two genetic models (recessive model: I² = 49.9%, P = 0.112; homozygous model: I² = 48.0%, P = 0.123) used random-effect model and a fixed-effect model was used (Table 2).

Metabolizer phenotypes and ESCC risk

Based on metabolizer phenotype, individuals including 1955 cases and 2602 controls were divided into three groups: EMs (*1/*1); IMs (*1/*2, *1/*3); and PMs (*2/*2, *3/*3 and *2/*3). As shown in Table 3, the results of the meta-analysis showed that there were significant differences in the risk of ESCC in the following comparisons: between IMs group and EMs group (OR = 1.673, 95% CI = 1.281–2.186), between PMs group and EMs group (OR = 2.605, 95% CI = 1.945–3.489), between PMs group and IMs group (OR = 1.685, 95% CI = 1.154–2.459), between PMs group and EMs group + IMs group (OR = 2.220, 95% CI = 1.705–2.891) (Fig. 4). Heterogeneity analysis showed significant inter-study variation in two comparisons (IMs vs. EMs: I² = 56.4%, P = 0.032; PMs vs. IMs + EMs: I² = 52.4%, P = 0.161).
Publication bias

Figure 5 (A and B) showed the funnel plots for association between CYP2C19*2, CYP2C19*3 polymorphisms and ESCC risk, which reveal no visually significant publication bias. The $P$-values for both Begg’s and Egger’s tests (CYP2C19*2: $P_{\text{Begg}} = 0.452$ and $P_{\text{Egger}} = 0.406$; CYP2C19*3: $P_{\text{Begg}} = 1.000$ and $P_{\text{Egger}} = 0.822$) indicated no publication bias, respectively. Figure 5 (C) shows the funnel plots for the association between the metabolizer phenotypes and ESCC risk. No publication bias was found in IMs and EMs group ($P_{\text{Begg}} = 1.000$, $P_{\text{Egger}} = 0.760$). Three groups (PMs and EMs: $P_{\text{Begg}} = 0.368$, $P_{\text{Egger}} = 0.053$; PMs and IMs: $P_{\text{Begg}} = 0.368$, $P_{\text{Egger}} = 0.075$; PMs and EMs + IMs: $P_{\text{Begg}} = 0.368$, $P_{\text{Egger}} = 0.083$) showed significant publication bias.

Sensitivity analysis

The sensitivity analysis was carried out by repeating the analysis after sequentially omitting each study to investigate the causes for heterogeneity. As a result, no significant effect was shown in ORs of CYP2C19*2, CYP2C19*3 genotypes and metabolizer phenotypes (Fig. 6).

Discussion

Previous studies regarding the association between CYP2C19 gene polymorphisms and the risk of ESCC remain inconsistent and inconclusive. This meta-analysis aimed to explore the association between CYP2C19 gene polymorphisms and ESCC risk. Among the results, people carrying the CYP2C19*2 gene A allele had a high ESCC risk compared to people carrying the G allele (OR = 1.823, 95% CI = 1.616–2.056). In previous study, the result was inconsistent in CYP2C19*3 gene polymorphism. Wei et al. found that there was no association between CYP2C19*3 gene polymorphism and ESCC risk in 2004 [22], whereas Yun et al. reported that CYP2C19*3 gene A allele showed significantly more prevalent in ESCC patients in 2012 [19]. This meta-analysis combined the results of 6 associated studies and found that AA genotype of CYP2C19*3 polymorphism was related to ESCC risk (OR = 2.992, 95% CI = 1.122–7.981). CYP2C19*2 G681A and CYP2C19*3 G636A genes have single base mutations, resulting in reduced CYP2C19 enzyme activity and slowed metabolism of the carcinogens, which accumulate in the body as exposed time and dose increase, contributing to the susceptibility to ESCC [27]. CYP2C19 can be divided into EMs, IMs and PMs phenotypes by metabolic capacity. The results confirmed that IMs had a higher risk of ESCC than EMs (OR = 1.673, 95% CI = 1.281–2.186); PMs had a higher risk of ESCC than IMs (OR = 1.685, 95% CI = 1.154–2.459). And PMs was associated with a higher risk than EMs + PMs (OR = 2.220, 95% CI = 1.705–2.891). This meta-analysis suggested that the lower CYP2C19 enzyme active, the higher ESCC risk.

CYP2C19 is a member of the cytochrome P450 superfamily which acts on substances from drugs or environment. Previous studies indicated that CYP2C19 may affect the occurrence of tumors by participating both in activation of procarcinogen and detoxification of carcinogens. Wei et al. used the ASA-PCR method to perform CYP2C19 allele analysis on 372 healthy controls and patients with 212 lung cancer, 148 gastric cancer, 135 esophageal cancer and 112 bladder cancer [22]. The results suggested
CYP2C19 PMs had a high incidence of ESCC, lung cancer and stomach cancer. In contrast, PMs had a low incidence of bladder cancer. In 2014, Li et al. conducted a study in Han population and founded that individuals with variant genotypes of CYP2C19 (*2/*2, *2/*3, *3/*3) have increased risk of getting primary liver cancer [28]. Anna et al. reported a significant association of CYP2C19 deletion allele with triple-negative breast cancer in Finnish population [29] and Jabir et al. found the association of CYP2C19 polymorphism with breast cancer in Iraqi population [30], whereas Laith et al. found no association with breast cancer in Japanese people [31]. The above results suggested poor metabolism in CYP2C19 increases the risk of EC, gastric cancer, lung cancer, and liver cancer. On the other hand, CYP2C19 PMs can reduce the risk of bladder cancer.

To our knowledge, this is the first meta-analysis to assess the association between the CYP2C19 polymorphisms and phenotypes with the risk of ESCC in Asian. But there are some limitations in this study. First, only 8 articles were included in the analysis. Small sample size may affect our results. Second, 3 of the included studies were PhD thesis and only 6 studies were available for each CYP2C19 genotypes analysis, which may affect our statistical power [32]. We conducted a sensitivity analysis and no impact on the results were shown. Third, the included populations were mainly concentrated in Asian populations (ie, Chinese and Indian), and no studies were from Caucasian or African populations [33]. To obtain more accurate conclusions, the inclusion of ethnic groups should be expanded, and subgroup analyses should be performed. We plan to follow up the research and expand the sample size to improve the results next.

Conclusions

In conclusion, our meta-analysis demonstrated that “A” allele of CYP2C19*2 G681A and AA genotype of CYP2C19*3 G636A polymorphism are significantly associated with the risk of ESCC. In metabolizer phenotypes, PMs and IMs groups may be associated with an increased ESCC risk. The results should be confirmed by collecting more case–control studies.

Abbreviations

CYP2C19
Cytochrome P450 2C19; EC:esophageal carcinoma; ESCC:esophageal squamous cell cancer; EADC:Esophageal adenocarcinoma; EMs:extensive metabolizers; IMs:intermediate metabolizers; PMs:poor metabolizers; CNKI:China National Knowledge Internet; OR:odds ratio; CI:confidence interval; NOS:Newcastle-Ottawa scale; PCR:polymerase chain reaction; RFLP:restriction fragment length polymorphism; ASA, allele specific amplification; Ph: P-value of the heterogeneity test.

Declarations

Authors’ contributions
XH G designed the study. XH G, GG W, ZK, YQ Wand JQ Z performed the literature search, data collection, statistical analysis and data Interpretation. XH G, LL and SQ L drafted the manuscript. All authors read and approved the final manuscript.

Author details

1 Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Competing interests

The authors have declared no competing interests.

Funding

The authors received no specific funding for this work.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Acknowledgements

Not applicable.

References

1. Gautam K, Malhotra U, Yanala A, Ravipati, et al. Global trends in esophageal cancer. J Surg Oncol. 2017;9999:16. doi:10.1002/jso.24592.

2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.

3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E86. doi:10.1002/ijc.29210.

4. 10.1053/j.gastro.2017.08.023
Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous Cell Carcinoma. *Gastroenterology* 2018;154(2):360 – 73. doi: 10.1053/j.gastro.2017.08.023.

5. Bhat GA, Shah IA, Rafiq R, et al. Family history of cancer and the risk of squamous cell carcinoma of oesophagus: a case-control study in Kashmir, India. *Br J Cancer*. 2015;113(3):524–32. doi:10.1038/bjc.2015.218.

6. Helsby NA. CYP2C19 and CYP2D6 genotypes in Pacific peoples. *Br J Clin Pharmacol.* 2016;82(5):1303–07. doi:10.1111/bcp.13045 [published Online First: 2016/06/16].

7. 10.2217/pgs-2017-0194

   Bahar MA, Setiawan D, Hak E, et al. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. *Pharmacogenomics* 2017;18(7):701 – 39. doi: 10.2217/pgs-2017-0194 [published Online First: 2017/05/10].

8. Dehbozorgi M, Kamalidehghan B, Hosseini I, et al. Prevalence of the CYP2C19*2 (681 G > A), *3 (636 G > A) and *17 (806 C > T) alleles among an Iranian population of different ethnicities. *Mol Med Rep.* 2018;17(3):4195–202. doi:10.3892/mmr.2018.8377.

9. Xi Z, Fang F, Wang J, et al. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis. *Platelets*. 2019;30(2):229–40. doi:10.1080/09537104.2017.1413178.

10. Zhong Z, Hou J, Li B, et al. Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China. *Medical science monitor: international medical journal of experimental clinical research*. 2017;23:6186–92. doi:10.12659/msm.905337 [published Online First: 2017/12/31].

11. Sorich MJ, Rowland A, McKinnon RA, et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. *Circ Cardiovasc Genet*. 2014;7(6):895–902. doi:10.1161/CIRCGENETICS.114.000669.

12. Math N, Han TS, Lubomirova I, et al. Influences of genetic variants on stroke recovery: a meta-analysis of the 31,895 cases. *Neurol Sci*. 2019;40(12):2437–45. doi:10.1007/s10072-019-04024-w.

13. Chang M, Tybring G, Dahl ML, et al. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. *Clin Pharmacokinet*. 2014;53(9):801–11. doi:10.1007/s40262-014-0162-1 [published Online First: 2014/08/27].

14. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama*. 2000;283(15):2008–12. doi:10.1001/jama.283.15.2008 [published Online First: 2000/05/02].

15. Wang H, Gao X, Zhang X, et al. Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis. *Medical science monitor: international medical journal of experimental clinical research*. 2018;24:7482–92. doi:10.12659/MSM.912373.
16. Bowden J, Tierney JF, Copas AJ, et al. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41. doi:10.1186/1471-2288-11-41.

17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi:10.1007/s10654-010-9491-z [published Online First: 2010/07/24].

18. Bhat GA, Bhat AB, Lone MM, et al. Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir. Nutr Cancer. 2017;69(4):585–92. doi:10.1080/01635581.2017.1299874.

19. Shi Y, Luo G-j, Zhang L, et al. Interaction between Alcohol Consumption and CYP 2C19 Gene Polymorphism in Relation to Oesophageal Squamous Cell Carcinoma. PLoS ONE. 2012;7(9):e43412. doi:10.1371/journal.pone.0043412.

20. Peng XE, Chen HF, Hu ZJ, et al. Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China. BMC Med Genet. 2015;16:15. doi:10.1186/s12881-015-0156-3.

21. Chen HF, Shi XY, Tian S. the relation between Genetic Polymorphism of Cytochrome CYP2C19(P4502C19) and susceptibility to esophageal cancerJ[D]. J Fujian Med Univ 2006.

22. Shi WX, Chen SQ. Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol. 2004;10(13):1961–3. doi:10.3748/wjg.v10.i13.463.

23. LW Z IS. MB W, et al. Study on relations between genetic polymorphisms in CYP2C19, GSTT1 and risk of Kazakh's esophageal cancer in Xinjiang. Journal of Practical Oncology. 2006;24:232–6.

24. Zhang L, Wang J. Analysis of the CYP2C19 Polymorphism and the Association with the Effects of Omeprazole[D]. JILIN UNIV 2004.

25. Youping Z, Yuefeng T, Luhang Z, et al. The association between cytochrome P4502C19 gene polymorphism and susceptibility to esophageal cancer. Chin J Med Gen et. 2000;17:3.

26. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007;7:5. doi:10.1186/1471-2288-7-5.

27. Zhang H, Li H, Yu H. Analysis of the role of rs2031920 and rs3813867 polymorphisms within the cytochrome P450 2E1 gene in the risk of squamous cell carcinoma. Cancer Cell Int. 2018;18:67. doi:10.1186/s12935-018-0561-8.

28. Li QY, Zhao NM, Wang LC, et al. Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus. Tumour Biol. 2014;35(9):9023–6. doi:10.1007/s13277-014-2144-1.

29. Tervasmäki A, Winqvist R, Jukkola-Vuorinen A. Recurrent. CYP2C19 deletion allele is associated with triple-negative breast cancer. BMC Cancer 2014;14 doi:10.1186/1471-2407-14-902.
30. Jabir FA, Hoidy WH. Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women. Clin Breast Cancer. 2018;18(5):e863-e68. doi:10.1016/j.clbc.2018.01.009.

31. Al-Eitan LN, Rababa’h DM, Alghamdi MA, et al. Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population. BMC Med Genet. 2019;20(1):148. doi:10.1186/s12881-019-0884-x.

32. Li S, Xue F, Zheng Y, et al. GSTM1 and GSTT1 null genotype increase the risk of hepatocellular carcinoma: evidence based on 46 studies. Cancer Cell Int. 2019;19:76. doi:10.1186/s12935-019-0792-3.

33. Yao L, Wang HC, Liu JZ, et al. Quantitative assessment of the influence of cytochrome P450 2C19 gene polymorphisms and digestive tract cancer risk. Tumour Biol. 2013;34(5):3083–91. doi:10.1007/s13277-013-0875-z [published Online First: 2013/06/12].

Tables
### Table 1
Characteristics of studies included in the systematic review and meta-analysis.

| Author               | Year | Country | Sample Size | No. of case/controls | Male (%) | Age (case/control) | Genotype alleles tested | Genotyping method | NOS |
|----------------------|------|---------|-------------|----------------------|----------|---------------------|------------------------|-------------------|-----|
| Gulzar Ahmad Bhat    | 2017 | India   | 984         | 492/4 92             | 56       | 60.2± 11.25 / 61.57 ±11.17 | CYP2 C19*1, *2 CYP2 D6 | PCR-RFLP         | 9   |
| Xian-E Peng          | 2015 | China   | 1710        | 570/1 140            | 59       | 59.67± 9.83 / 59.71 ±9.84 | CYP2 C19*1, *2,*3 | PCR-RFLP         | 8   |
| Yun Shi              | 2012 | China   | 700         | 350/3 50            | 60       | 59.4± 12.5/ 60.7± 12.4 | CYP2 C19*1, *3 | PCR-RFLP         | 9   |
| Hua-F Chen           | 2006 | China   | 776         | 258/5 18            | 61       | 59.78± 59.79         | CYP2 C19*1, *2,*3 | PCR-RFLP         | 8   |
| Li-W Zhang           | 2006 | China   | 160         | 88/72               | 59       | 55.77± 8.85 / 55.52 ±9.15 | MTHFR CYP2 C19*1, *2,*3 | PCR-RFLP         | 8   |
| Lin Zhang            | 2004 | China   | 62          | 12/50 NS            | NS       | NS/3 1.50± 8.45      | CYP2 C19*1, *2,*3 | PCR-RFLP         | 7   |
| Wei-X Shi            | 2004 | China   | 507         | 135/3 2             | NS       | NS                  | CYP2 C19*1, *2,*3 | ASA-PCR           | 8   |
| Wei-P Zhao           | 2000 | China   | 150         | 50/10 0             | NS       | NS                  | CYP2 C19*1, *2,*3 | PCR-RFLP         | 7   |

NS, not specified; NOS, Newcastle-Ottawa scale; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; ASA, allele specific amplification.
### Table 2
Meta-analysis of associations between CYP2C19*2 and CYP2C19*3 polymorphisms and ESCC risk.

| Model | Genotype | OR with 95% CI | Heterogeneity | Publication bias |
|-------|-----------|----------------|---------------|-----------------|
|       |           |                | $\chi^2$ | $P_h$ | $\phi^2$ | Begg | Egger |
|       |            |                |            |            |        |      |      |
| **CYP2C19*2** | | | | | | | |
| Dominant | AA+AG vs. GG | 2.406 (2.013-2.876) | 7.71 | 0.208 | 30.3% | 0.452 | 0.406 |
| Recessive | AA vs. AG+GG | 1.934 (1.533-2.439) | 6.51 | 0.260 | 23.2% | 0.009 | 0.019 |
| Homozygote | AA vs. GG | 4.467 (3.320-6.011) * | 63.92 | <0.001 | 92.2% | 0.707 | 0.727 |
| Heterozygote | GA vs. GG | 1.308 (1.073-1.596) * | 177.2 | <0.001 | 97.2% | 1.000 | 0.801 |
| Allele | A vs. G | 1.823 (1.616-2.056) | 3.04 | 0.694 | 0.0% | 0.452 | 0.512 |
| **CYP2C19*3** | | | | | | | |
| Dominant | AA+AG vs. GG | 1.206 (0.637-2.284) * | 16.27 | 0.006 | 69.3% | 0.707 | 0.760 |
| Recessive | AA vs. AG+GG | 2.992 (1.122-7.981) | 5.99 | 0.112 | 49.9% | 0.308 | 0.556 |
| Homozygote | AA vs. GG | 2.889 (1.073-3- | 5.77 | 0.123 | 48.0% | 0.308 | 0.626 |
Table 3
Meta-analysis of associations between CYP2C19 metabolizer phenotypes and ESCC risk.

| Metabolizer phenotype | OR with 95% CI | Heterogeneity | Publication bias |
|-----------------------|---------------|---------------|-----------------|
|                       |               | $\chi^2$ | $P_h$ | $I^2$ | Begg | Egger |
| IMs vs. EMs           | 1.673 (1.28-2.186) * | 13.76 | 0.032 | 56.4% | 1.000 | 0.760 |
| PMs vs. EMs           | 2.605 (1.94-3.489) | 8.15 | 0.227 | 26.4% | 0.368 | 0.053 |
| PMs vs. IMs           | 1.685 (1.15-2.459) | 11.23 | 0.161 | 46.6% | 0.368 | 0.075 |
| PMs vs. IMs + EMs     | 2.220 (1.70-2.891) * | 10.52 | 0.161 | 52.4% | 0.386 | 0.083 |

OR – odds ratio; 95% CI – 95% confidence interval; $\chi^2$ – chi-square; $I^2$ – I-squared; $P_h$ – $P$-value of the heterogeneity test. * A random-effects model was constructed.
Figure 1

Flowchart for inclusion of eligible studies.
Figure 2

Meta-analysis for CYP2C19*2 polymorphism and ESCC risk under the dominant model. The squares and horizontal lines represent OR and 95% CI, respectively. The area of the squares represents the study-specific weight.
Figure 3

Meta-analysis for CYP2C19*3 polymorphism and ESCC risk under the recessive model.
Figure 4

Forest plots of CYP2C19 metabolizer phenotypes and ESCC risk. a IMs and EMs; b PMs and EMs; c PMs and IMs; d PMs and EMs + IMs.
Figure 5

Funnel plots of publication bias of CYP2C19 gene polymorphisms. a CYP2C19*2 dominant model; b CYP2C19*3 recessive model; c PMs and EMs + IMs phenotype.

Figure 6

Sensitivity analysis of the associations between CYP2C19 polymorphisms with ESCC risk. a CYP2C19*2; b CYP2C19*3; c PMs and EMs + IMs.